Plus Therapeutics Inc Stock

$1.17

7.14% yesterday

Nasdaq, Nov 15, 10:08 pm CET

ISIN

US72941H4002

Symbol

PSTV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Plus Therapeutics Inc Stock price

$1.17

-39.48 97.12% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

-0.09 7.14%

ISIN

US72941H4002

Symbol

PSTV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$6.90m
Enterprise Value	$5.51m
P/E (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	0.96
P/S ratio (TTM) P/S ratio	1.20
P/B ratio (TTM) P/B ratio	negative
Revenue growth (TTM) Revenue growth	52.63%
Revenue (TTM) Revenue	$5.73m
EBIT (operating result TTM) EBIT	$-14.66m
Cash position	$8.44m
EPS (TTM) EPS	$-2.24
P/E forward	negative
P/S forward	1.41
EV/Sales forward	0.46
Short interest	0.90%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Plus Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Plus Therapeutics Inc forecast:

4x Buy

100%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Plus Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Plus Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	5.73 5.73	53% 53% 100%
- Direct Costs	- -	- -
Gross Profit	4.92 4.92	70% 70% 86%
- Selling and Administrative Expenses	- -	- -
- Research and Development Expense	11 11	24% 24% 195%
EBITDA	- -	- -
- Depreciation and Amortization	0.80 0.80	6% 6% 14%
EBIT (Operating Income) EBIT	-15 -15	3% 3% -256%
Net Profit	-13 -13	15% 15% -225%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Plus Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

one day ago

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium ( 186 Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReSPECT-GBM Trial Data at the 2024 Congress of Neurological Surgeons Annual Conference Established Radiotherapeutic Manufacturing Partnership with SpectronRx to meet late-stage clinical and commerci...

Neutral

GlobeNewsWire

●

10 days ago

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

AUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, and SpectronRx , a leading radiopharmaceutical contract developer and manufacturer, announced the signing of a Manufacturing Services Agreement (MSA) for the production o...

Neutral

GlobeNewsWire

●

11 days ago

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus The...

More Plus Therapeutics Inc News

Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its products include Rhenium NanoLiposome (RNL) and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Head office	United States
CEO	Marc Hedrick
Employees	20
Founded	1996
Website	www.plustherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now